Home Members Tools Credit Cards
   

RIGL Stock Quote and Technical Analysis

Portfolios Markets Resources
  Symbol List
Rigel Pharmaceuticals, Inc. (RIGL)
▲ 2.15 (+0.08) 3.86%
Open: 2.09
High: 2.16
Low: 2.04
Afterhours: N/A - N/A
Volume: 262482
1/29/2015 4:00pm
 
Interactive Chart
EPS: -0.976 (Current Year Estimated: -1.04)
Dividend: N/A
P/E: N/A

Technicals:
52 Week Range: 1.56 - 5.00
50 Day Moving Average: 2.213
200 Day Moving Average: 2.3246
Pivot Point: Not Available

Login or signup free to Add "RIGL" to your portfolio

Resources:

News:


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Fri, 09 Jan 2015 21:16:33 GMT


Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Thu, 08 Jan 2015 12:57:10 GMT
[at noodls] - SOUTH SAN FRANCISCO, Jan. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present updated ...

Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Thu, 08 Jan 2015 12:30:00 GMT
[PR Newswire] - AstraZeneca's continued efforts to develop R256, Rigel's inhaled JAK inhibitor, as a potential treatment for asthma, triggered a milestone payment of $5.75 million that Rigel earned in December 2014. AstraZeneca and Rigel entered an exclusive worldwide license agreement for the global development and commercialization of R256 in June 2012. Partners BerGenBio and Daiichi Sankyo are developing Rigel's AXL kinase inhibitor and an ubiquitin ligase inhibitor, respectively, for their potential safety and efficacy in treating various cancers. Both of these molecules are currently in Phase 1 clinical development.

Art Levinson's aging research company Calico snags South S.F. space
Wed, 24 Dec 2014 18:20:09 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Mon, 24 Nov 2014 21:16:19 GMT


Rigel Announces Executive Management Changes
Mon, 24 Nov 2014 12:44:03 GMT
[at noodls] - SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman ...

Rigel Announces Executive Management Changes
Mon, 24 Nov 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and join the board of directors. Gary Lyons, a member of Rigel's Board of Directors since 2005, will become chairman. Mr. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters.

RIGEL PHARMACEUTICALS INC Financials
Fri, 14 Nov 2014 18:04:38 GMT


10-Q for Rigel Pharmaceuticals, Inc.
Fri, 07 Nov 2014 00:08:37 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Tue, 04 Nov 2014 21:20:12 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Tue, 04 Nov 2014 18:47:09 GMT


Rigel posts 3Q loss
Tue, 04 Nov 2014 14:37:01 GMT


Rigel posts 3Q loss
Tue, 04 Nov 2014 14:37:01 GMT


Rigel Announces Third Quarter 2014 Financial Results
Tue, 04 Nov 2014 13:20:38 GMT
[at noodls] - News Release SOUTH SAN FRANCISCO, Calif., Nov. 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, ...

Rigel Announces Third Quarter 2014 Financial Results
Tue, 04 Nov 2014 12:30:00 GMT
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., Nov. 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2014. For ...

Rigel's R348 Fails in Phase II Study, Shares Down 13.6%
Thu, 14 Aug 2014 18:30:03 GMT


Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today
Wed, 13 Aug 2014 19:37:00 GMT


Rigel eye drug fails mid-stage study, shares fall
Wed, 13 Aug 2014 14:48:52 GMT


RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed, 13 Aug 2014 12:00:35 GMT


Rigel experimental eye drug fails mid-stage study
Wed, 13 Aug 2014 11:44:34 GMT


All Company News is Powered by Yahoo! Finance

 

 

 

Credit Cards | Finance Social Network | Credit Card Reviews | Markets
About Us | FG on the Web | Sitemap | Privacy | Terms | Contact


Copyright © 2015 Finance Globe. All rights reserved.